Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
BOTHELL, Wash., Jan. 5, 2021 – Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that management will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOTHELL, Wash., Jan. 5, 2021 – Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that management will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be accessible on the company’s website starting January 11, 2021, at 6:00 a.m. Eastern time. CEO Gary Wilcox highlighted the company's progress in advancing its pipeline of novel antiviral compounds during 2020 and expressed anticipation for discussing upcoming milestones at the conference.
For more details about Cocrystal, visit www.cocrystalpharma.com.
Details
News Market Reaction – COCP
The recorded move for COCP in the trading session of this news was +1.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces management will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021. The presentation can be accessed on the IR Calendar section of the Cocrystal website beginning on January 11, 2021 at 6:00 a.m. Eastern time.
“We are pleased with our progress in 2020 in advancing our pipeline of novel antiviral compounds,” said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal. “We look forward to presenting at this conference and introducing upcoming milestones.”
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.